Shanghai XinXing Medical

Shanghai Xinxing Medicine was a China-based blood products manufacturer focused on the research, production, and sale of plasma-derived therapeutics. Its marketed portfolio included human albumin, intravenous human immunoglobulin, prothrombin complex concentrate, fibrinogen, hepatitis B immunoglobulin, rabies immunoglobulin, and fibrin sealant-related products. The company was historically controlled by China Meheco and operated GMP-certified manufacturing facilities together with plasma collection subsidiaries. Following a major 2019 product safety crisis and prolonged operational disruption, the company was renamed in 2023 to Noyi Biopharma, so the original "Shanghai Xinxing Medicine" name appears to be a former corporate name rather than the currently active operating name.